news
LSD Flips Gene Signatures of Brain Aging in New Study
A study in Aging Cell found that lysergic acid diethylamide triggers transcriptional changes that directly oppose genetic markers of brain aging and neurodegeneration. Researchers showed the compound downregulates neuroinflammation while boosting pathways responsible for synaptic plasticity and neuronal maintenance. The data provides genetic evidence that 5-HT2A receptor agonism shifts the molecular pace of cognitive decline.
A study in Aging Cell found that lysergic acid diethylamide triggers transcriptional changes that directly oppose genetic markers of brain aging and neurodegeneration. Researchers showed the compound downregulates neuroinflammation while boosting pathways responsible for synaptic plasticity and neuronal maintenance. The data provides genetic evidence that 5-HT2A receptor agonism shifts the molecular pace of cognitive decline.
The architecture take
I used to write off psychedelic longevity hype as venture-backed wishful thinking (mostly because the biohacker bragging sounded exhausting). Silicon Valley microdosers insisting their midday tabs cleared cellular debris felt like parody. But this transcriptomic data gives the idea actual teeth. The researchers mapped how LSD alters cortical gene expression, finding it directly dials down neuroinflammatory pathways and ramps up synaptic plasticity markers that typically decay with age. In plain terms, the compound reverses transcriptional signatures tied to Alzheimer's and cognitive decline, acting through 5-HT2A serotonin receptors to prompt neuronal repair. I still don't suggest dropping acid to protect your hippocampus before work. The jump from tissue-level RNA shifts to practical human routines is wide, messy, and legally blocked in most postal codes. What I'm watching instead is how quickly biotech labs try to strip the hallucination from the molecule. That race is officially on.